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Marginalized chromatinRecombinant virus HSV-1(RF177) was previously generated to examine tegument protein VP22 function by
inserting the GFP gene into the gene encoding VP22. During a detailed analysis of this virus, we discovered
that RF177 produces a novel fusion protein between the last 15 amino acids of VP22 and GFP, termed GCT-
VP22. Thus, the VP22 carboxy-terminal speciﬁc antibody 22-3 and two anti-GFP antibodies reacted with an
approximately 28 kDa protein from RF177-infected Vero cells. GCT-VP22 was detected at 1 and 3 hpi.
Examination of puriﬁed virions indicated that GCT-VP22 was incorporated into RF177 virus particles. These
observations imply that at least a portion of the information required for virion targeting is located in this
domain of VP22. Indirect immunoﬂuorescence analyses showed that GCT-VP22 also localized to areas of
marginalized chromatin during RF177 infection. These results indicate that the last ﬁfteen amino acids of
VP22 participate in virion targeting during HSV-1 infection.© 2009 Elsevier Inc. All rights reserved.IntroductionThe tegument of the herpes simplex virus particle is the
proteinaceous layer located between the capsid and envelope and is
made up of approximately 20 virus-encoded polypeptides (Enquist et
al., 1998; Mettenleiter, 2002; Mettenleiter, 2004; Roizman, 1974;
Vittone et al., 2005). While it is unclear howHSV-1 virions assemble, a
number of interactions involving HSV-1 tegument protein self- and
nonself-associations have been identiﬁed (Elliott, Mouzakitis, and
O'Hare, 1995; Hafezi et al., 2005; Lee et al., 2008; Mouzakitis et al.,
2005; Smibert et al., 1994; Taddeo et al., 2007; Vittone et al., 2005).
Some viral tegument proteins reportedly interact with the cytoplas-
mic tail of certain viral glycoproteins (Chi et al., 2005; Farnsworth,
Wisner, and Johnson, 2007; Fuchs et al., 2002; Gross, Harley, and
Wilson, 2003) and this may impact virion assembly (Leuzinger et al.,
2005; Mettenleiter, 2004; O'Regan et al., 2007; Sugimoto et al., 2008).
VP22, which contains 301 amino acids, is the most abundant
tegument protein of HSV-1; nearly 2000 copies of VP22 are estimated
to be present within each virion (Heine et al., 1974). VP22 is a
posttranslationally modiﬁed phosphoprotein (Blaho, Mitchell, and
Roizman, 1993; Elliott, O'Reilly, and O'Hare, 1996; Elliott, O'Reilly, and
O'Hare, 1999; Hutchinson et al., 2002; Knopf and Kaerner, 1980;
Morrison et al., 1998; Morrison, Wang, and Meredith, 1998; Pomeranz
and Blaho, 1999; Spear and Roizman, 1972) that exhibits multiplell rights reserved.subcellular localizations during productive viral infection (Elliott and
O'Hare, 1997; Elliott and O'Hare, 1999; Hafezi et al., 2005; Kotsakis
et al., 2001; Pomeranz and Blaho, 1999; Sugimoto et al., 2008;
Yedowitz et al., 2005). VP22 accumulates to high levels in nuclei at late
infection times (Pomeranz and Blaho,1999; Sugimoto et al., 2008) and
it associates with areas of dispersed nucleoli and marginalized
chromatin (Lopez et al., 2008). Transiently expressed VP22 has been
detected in both the cytoplasm and nuclei of cells (Blouin and Blaho,
2001; Brignati et al., 2003; Elliott and O'Hare, 2000; Fang et al., 1998;
Harms et al., 2000). While the predicted molecular weight of VP22 is
32,000 (Elliott and Meredith, 1992; McGeoch et al., 1988), which is
below the size exclusion limit (molecular weight of 40,000 to 45,000)
for passive diffusion through the nuclear pore (Davis, 1995), VP22
contains two computer predicted nuclear localization signal motifs
(Harms et al., 2000; Kotsakis et al., 2001).
In an attempt to determine the biological function of VP22 during
viral infection, a recombinant virus, HSV-1(RF177), was generated
which contains a carboxy-terminal truncation of VP22 and synthe-
sizes amino acids 1 to 212, termed Δ212 (Pomeranz and Blaho, 2000).
Tegument proteins VP13/14, VP16, and vhs were synthesized and
incorporated into RF177 virions at wild type levels but RF177
demonstrated a small plaque size phenotype. These initial studies
suggested a cell–cell spreading defect for viruses containing defects in
VP22 (Pomeranz and Blaho, 2000) which has since been deﬁnitively
conﬁrmed (Duffy et al., 2006; Duffy, Mbong, and Baines, 2009). A
further analysis revealed that RF177 produced a novel VP22-GFP
fusion protein, which we term GCT-VP22. Our goal was to characterize
the behavior of GCT-VP22 during productive RF177 infection. GCT-
Fig. 1. Schematic representation of the HSV-1(F) genome and details of the mutated
gene loci of HSV-1(RF177). Line 1 — the HSV-1 (F) genome with the unique long (UL),
unique short (US), and terminal repeat segments (a, b, c, a′, b′, and c′) indicated.
Coordinates of the BamF fragment are indicated. Line 2 — gene UL49 encoding full-
length, wild type (WT)VP22 showing approximate locations of pat4 and pat7 nuclear
localization signal motifs. Solid arrowhead shows the direction of transcription. Line 3—
insertion of GFP expression cassette into the carboxy-terminus of the UL49 gene in HSV-
1(RF177) introduces a stop codon at histidine 212 in VP22 to produce the carboxy-
terminal truncation (212 protein. Line 4— orientation of GFP indicating that a portion of
UL49 remains at its carboxy-terminus and the potential for a GFP carboxy-terminal
VP22 (GCT-VP22) chimera. Line 5— sequence of the in frame amino acids between GFP
and 45 bp of the VP22 carboxy-terminus. Line 6 — schematic of VP22 showing its ER
membrane retention motif (TSRR) (Kotsakis et al., 2001), CKII phosphorylation targets
at serine (S) 71–73 (Elliott, O'Reilly, and O'Hare, 1996; Elliott, O'Reilly, and O'Hare,
1999), and serines (SS) at amino acids (aa) 292 and 294 phosphorylated by unspeciﬁed
kinases (Elliott, O'Reilly, and O'Hare, 1999). The location of tyrosine 38 which is
phosphorylated in BHV-1 VP22 (Ren, Harms, and Splitter, 2001) is indicated. PRAPR
refers to the alpha protein basic site (Blaho, Mitchell, and Roizman, 1994). The pat7 and
pat4 nuclear localization signal motifs are shown (Kotsakis et al., 2001).
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information required for virion targeting was located in the last 15
amino acids of VP22. We identiﬁed a motif of six consecutive amino
acids in this region that was conserved among the HSV-1, HSV-2, and
VZV VP22 homologues and we hypothesize that this motif might
function as a virion packaging signal. Finally, we discovered that GCT-
VP22 targeted marginalized chromatin during RF177 infection. TheseFig. 2. Immune reactivities of RF177-infected cell extracts. Vero cells were infected (MOI of
transferred to nitrocellulose, and probed with polyclonal (pAb) RGST49 (A), monoclonal (m
Secondary antibodies were conjugated to either horseradish peroxidase for development b
truncated (212 are indicated. GCT-VP22 refers the location of the protein detected by 22-3 a
faster migrating minor bands in B and D likely represent protein degradation products deteﬁndings suggest that we have identiﬁed a multifunctional, carboxy-
terminal domain in VP22 that likely inﬂuences its subcellular
localization and virion packaging during productive HSV-1 infection.
Results
HSV-1(RF177) synthesizes a carboxy-terminal VP22-GFP fusion protein
termed, GCT-VP22
We previously reported that the recombinant virus HSV-1(RF177),
termed RF177, synthesizes the amino-terminal 212 amino acids of
VP22 (Δ212) which localizes to nuclei and incorporates into virions
during RF177 infection of Vero cells (Pomeranz and Blaho, 2000).
RF177 has been a useful research tool as it deﬁned the roles of VP22 in
viral cell–cell spreading (Pomeranz and Blaho, 2000) and efﬁcient
microtubule reorganization during HSV-1 infection (Yedowitz et al.,
2005). To generate RF177, a cytomegalovirus promoter-driven green
ﬂuorescence protein (GFP) cassette was inserted after amino acid 212
of VP22 (Pomeranz and Blaho, 2000). This strategy left approxi-
mately 45 bp at the 3′ end of the UL49 gene (Fig. 1, line 3). A careful
inspection of the nucleotide sequences of GFP, the remaining region
of the multiple cloning site (linker), and the remaining portion of
VP22 indicated that a likely in frame fusion occurred when
generating recombinant virus RF177 (Fig. 1, line 5). To conﬁrm the
existence of this putative GFP-carboxy-terminal VP22 fusion (line 4),
Vero cells were mock-infected or infected (MOI=5) with HSV-1(F)
or RF177, whole cell extracts were prepared at 24 hpi, separated in a
denaturing gel, transferred to nitrocellulose, and probed with the
antibody 22-3, speciﬁc for the carboxy-terminal portion of VP22
(Geiss et al., 2001) and control RGST49 antibody, speciﬁc for the
amino-terminal portion, as described in Materials and methods. We
then reprobed the blots with anti-GFP polyclonal and monoclonal
antibodies, accordingly. The results (Fig. 2) from theses experiments
were as follows.
No viral proteins were detected in mock-infected cells (Figs. 2A–D,
lane 3). As expected, both RGST49 and 22-3 antibodies reacted with
full-length VP22 in HSV-1(F)-infected cells (Figs. 2A, lane 1 and C, lane
2). Multiple forms of VP22 were observed as described previously
(Blaho, Mitchell, and Roizman, 1994; Pomeranz and Blaho, 1999). Low
levels of Δ212 were detected in RF177-infected cells using RGST49
(Fig. 2A, lane 2) while no immune reactionwas observed with the 22-
3 antibody in the portion of the blot where Δ212 migrates (Fig. 2C,
lane 3). However, the VP22 carboxy-terminal speciﬁc antibody 22-3
reactedwith an approximately 28,000molecular weight protein in the5) for 24 hpi, equal amounts of whole cell extract were separated in a denaturing gel,
Ab) 22-3 (C), and anti-GFP (B and D) antibodies as described in Materials and methods.
y ECL (A, B, and D) or alkaline phosphatase (C). The locations of full-length VP22 and
nd anti-GFP antibodies. Locations of molecular weight markers (kDa) are indicated. The
cted with the anti-GFP antibodies.
Fig. 3. Immune reactivities of infected cell proteins extracted during the course of
synchronized HSV-1(F) and RF177 infections. Vero cells were synchronously infected
with HSV-1(F) and RF177 or mock-infected. At 1, 3, 5, 7, and 24 hpi, whole cell extracts
were prepared, polypeptides were separated in denaturing gels, and transferred to
nitrocellulose prior to reacting with anti-VP22 (RGST49, speciﬁc for amino-terminal
VP22) (A) and -GFP (B) antibodies as described in Materials and methods. As a control,
each blot was also probed with anti-ICP4 antibody (A, B). The locations of the molecular
weight (m.w.) markers (kDa) are indicated. GCT-VP22 refers to the novel fusion protein
produced by RF177.
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with the carboxy-terminal speciﬁc antibody implies that this portion
of VP22 was being synthesized. Whenwe reprobed the blots (Figs. 2A,
C) with different anti-GFP antibodies, we found that both of these
antibodies also reacted with approximately 28,000 molecular weight
proteins in RF177-infected cell extracts (Figs. 2B, D, lane 2). Taken
together, these ﬁndings indicate that an in frame GFP fusion occurred
with the carboxy-terminal 15 amino acids of VP22. We propose the
term, GCT-VP22, for this GFP-carboxy-terminal VP22 fusion (Fig.1, line
4). GCT-VP22 was not detected in the original description of RF177
because only amino-terminal speciﬁc antibodies were used to
characterize the VP22 forms produced by this virus.
Full-length VP22 is a highly posttranslationally modiﬁed phos-
phoprotein (Blaho, Mitchell, and Roizman, 1994; Elliott, O'Reilly, and
O'Hare, 1996; Geiss et al., 2004; Geiss et al., 2001; Heine et al., 1974;
Pomeranz and Blaho, 1999) whose modiﬁcations correlate with its
translocation to nuclei (Pomeranz and Blaho,1999). While most of the
reported VP22 posttranslational modiﬁcation target sites remain in
Δ212, two serines (at amino acids 292 and 294) are located in GCT-
VP22 (Fig. 1, line 6). Serine phosphorylation has been proposed to play
a role in virion detegumentation (Morrison, Wang, and Meredith,
1998). Earlier computational analyses identiﬁed two possible nuclear
localization signal motifs in the primary structure of VP22 (Kotsakis et
al., 2001). The pat4 motif is a four residue pattern composed of three
basic amino acids and either an histidine or a proline residue. The pat7
motif starts with a proline followed within three residues by a basic
segment containing three lysine or arginine residues out of four.
VP22's pat7 motif starts at amino acid 82 (82PRTRRPV88) and pat4
motif starts at amino acid 295 (295RPRR298) (Fig. 1, lines 2 and 6). It
should be noted that certain viral nuclear localization signals may also
act as nucleolar localization signal motifs (Hiscox, 2002; Rowland and
Yoo, 2003). The GCT-VP22 protein produced during RF177 infection
contains only the pat4 motif. Therefore, the initial goal of this study
was to determine the cellular distribution and kinetics of synthesis of
GCT-VP22 to determine whether pat4 might participate in its
subcellular localization.
GCT-VP22 detected during RF177 infection
Fortuitously, because GCT-VP22 was formed during the generation
of RF177, this now enables us to deﬁne the role of the last 15 amino
acids of VP22 in the subcellular localization of GFP during live viral
infection. Our next goal was to characterize the kinetics of GCT-VP22
production. Vero cells were synchronously infected either with HSV-1
(F) or RF177, whole cell extracts were prepared at 1, 3, 5, 7, and 24 hpi,
separated in denaturing gels, transferred to nitrocellulose, and probed
with anti-ICP4, -VP22, and -GFP antibodies, as described in Materials
and methods. The results (Fig. 3) were as follows.
Low levels of ICP4 were detected at 3 hpi in cells infected with
HSV-1(F) or RF177 (Figs. 3A, B, lane 5) and ICP4 increased at 5 and
7 hpi, reaching a maximum at 24 hpi (lanes 6–8). Using anti-VP22
(RGST49) antibody, VP22 in HSV-1(F)-infected Vero cells was ﬁrst
detected at 5 hpi, increased slightly at 7 hpi, and accumulated at high
levels at 24 hpi (Fig. 3A, lanes 6–8). As expected, no ICP4 or VP22 was
observed in the mock-infected cells (Fig. 3A, lanes 2 and 3). In RF177-
infected cells, similar amounts of GCT-VP22 were detected at 5 and
7 hpi using anti-GFP antibody (Fig. 3B, lanes 6 and 7) and its
reactivity reached a high level at 24 hpi (lane 8). Unexpectedly, faint,
but discernable bands were observed reacting with the anti-GFP-
antibody at 1 and 3 hpi in the region of the blot where GCT-VP22
migrated (lanes 4 and 5). These ﬁndings raise the intriguing
possibility that GCT-VP22 might be packaged into virions and
transported into the cell at the onset of infection. The implication
of such an effect would be that, perhaps, some sort of a VP22
packaging signal may be located within the carboxy-terminal 15
amino acids of VP22.Close inspection of the results in Fig. 3B indicated a slight
difference in GCT-VP22 mobility between 1, 3 hpi and 5–24 hpi
(compare lanes 4, 5 with 6–8), inasmuch as VP22 at 1 and 3 hpi
migrated slightly slower (Pomeranz and Blaho, 1999). We previously
reported electrophoretic differences of VP22 depending upon its
subcellular localization and presence in virions (Blaho, Mitchell, and
Roizman, 1994; Pomeranz and Blaho, 1999; Pomeranz and Blaho,
2000). As these data are derived from whole infected cell extracts,
VP22 localization cannot be assessed. However, this observation
seems to support the notion that VP22 detected as a very early, slower
migrating form (Pomeranz and Blaho, 1999) is from input virus and
may reﬂect immediate posttranslational modiﬁcation, as proposed
(Morrison, Wang, and Meredith, 1998).
GCT-VP22 incorporation into RF177 virions
The results above indicate that GCT-VP22 could be detected at very
early times during RF177 infection, even before ICP4 was observed.
We therefore set out to determine whether GCT-VP22 might actually
be incorporated into RF177 virions (Pomeranz and Blaho, 1999). Vero
cells were infected with either HSV-1(F) or RF177, preparations of
puriﬁed HSV-1 and RF177 virions were made, virion proteins were
separated in a denaturing gel, transferred to nitrocellulose, and
sequentially probed with anti-VP22 polyclonal and -GFP monoclonal
antibodies as described in Materials and methods. The results (Fig. 4)
were as follows.
Abundant VP22 and a low amount of Δ212 was detected in the
virion preparations with the anti-VP22 polyclonal antibody following
HSV-1(F) and RF177 infections, respectively (Fig. 4A). As expected, no
anti-GFP reactivity was observed in virions of HSV-1(F) (Fig. 4B).
However, two bands reacting with the anti-GFP antibody were
observed in virion preparations derived from RF177. The mobility of
the upper band was consistent with that of GCT-VP22 (Fig. 2) and the
lower band likely represents a degradation product bound by this
antibody (as seen in Fig. 2). The lack of reactivity of GCT-VP22with the
anti-VP22 polyclonal antibody was expected as it is speciﬁc for the
amino-terminal domain (Fig. 2). We recognize that since we did not
Fig. 4. Immune reactivities of HSV-1(F) and HSV-1(RF177) virion proteins. Virions were
prepared from HSV-1(F)- and RF177-infected Vero cells as described in Materials and
methods. Virion proteins were separated in a denaturing gel, transferred to
nitrocellulose, and sequentially probed with anti-VP22 polyclonal (pAb) (A) and -GFP
monoclonal (mAb) (B) antibodies. Locations of full-length VP22, (212, and molecular
weight markers (kDa) are marked. GCT-VP22 refers to the novel fusion protein
produced by RF177.
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control recombinant in which GFP alone is produced under the same
regulatory control. However, the Courtney group has repeated shown
that GFP protein alone does not get packaged into virions during
productive HSV infection (O'Regan et al., 2007). Our data corroborate
the kinetic results above (Fig. 3) and demonstrate that GCT-VP22 was
incorporated into RF177 virions. Together, these results imply that
sufﬁcient amounts of virion associated GCT-VP22 are delivered into
RF177-infected cells to be detected by immunoblotting methods.
Full-length VP22 increases GCT-VP22 nuclear localization observed
during live RF177 infection
We performed two separate sets of experiments to document the
behavior of GCT-VP22 inside cells during the course of productive
virus infection. In our ﬁrst study, Vero and VP22-expressing V49 cellsFig. 5. Live ﬂuorescence microscopy of RF177-infected Vero and VP22-expressing V49 cells.
visualized live by ﬂuorescence microscopy as described in Materials and methods. Images owere synchronously infected with RF177 or mock-infected, Hoechst
33258 DNA dye was added to stain nuclei, and cells were visualized
live by ﬂuorescencemicroscopy at 18 hpi as described inMaterials and
methods. The results (Fig. 5) were as follows.
Inspection of the Hoechst-stained, live, infected cells indicated that
RF177 infection led to chromatin marginalization (compare panel H
with B and E), consistent with that observed with wild type HSV-1
(Lopez et al., 2008). This represents the ﬁrst description of this
phenomenon using RF177. GCT-VP22 synthesized during live RF177
infection of Vero cells was observed in both nuclei and the cytoplasm
(panel A). The cytoplasmic GCT-VP22 was readily discriminated in the
merged image (panel C). Since GCT-VP22 had a observed mol wt of
approximately 28,000 (Fig. 2), it should be small enough to pass freely
through the nuclear pore by diffusion (Pomeranz and Blaho, 2000)
and therefore might be expected to localize throughout the cell.
However, the extent of the nuclear localization of GCT-VP22 in V49
cells appeared greater than that with infected Vero cells (compare
panels D and A). No GFP signal was detected in mock-infected V49
cells (panels G and I). While these results may be slight, it is tempting
to speculate that the full-length VP22 present in the VP22-expressing
V49 cells may actually participate the nuclear localization of GCT-
VP22. During the original creation and characterizations of VP22
expressing cell lines (Blouin and Blaho, 2001; Kotsakis et al., 2001;
Pomeranz and Blaho, 2000), transient GFP expression in the presence
of VP22 alone did not show any differences in GFP localization from
that in GFP transfected non-VP22 expressing Vero cells. Based on this,
it seems unlikely that VP22 and GFP directly interact such that VP22
might affect GFP subcellular localization.
In the second study, Vero and V49 cells were synchronized HSV-1
(F)- or RF177-infected and stained with Hoechst, but the cells were
ﬁxed/permeabilized for indirect immunoﬂuorescence using the VP22
carboxy-terminal speciﬁc monoclonal antibody (22-3) as described in
Materials and methods. We also monitored GFP ﬂuorescence during
the RF177 infections and controls included using the VP22 amino-
terminal speciﬁc polyclonal antibody (RGST49) to detect full-length
VP22 in V49 cells. The results (Fig. 6) were as follows.
Since we were interested in following GCT-VP22 only, we ﬁrst
titrated down the 22-3 antibody to a level where its reactivity withVero and V49 cells were synchronously infected with RF177, stained with Hoechst, and
f control mock-infected V49 cells are shown. (Magniﬁcation, ×60).
Fig. 6. Indirect immunoﬂuorescence and GFP ﬂuorescence of HSV-1(F)- and RF177-infected Vero and V49 cells. Cells were uninfected (V49) (A), mock-infected (V49mock) (B. C),
synchronously infected with HSV-1(F) (B) or RF177 (C), or uninfected (V49) (C) and then ﬁxed, permeabilized, and stained with monoclonal antibody 22-3 (speciﬁc for VP22
carboxy-terminus) or polyclonal antibody RST49 (speciﬁc for VP22 amino-terminus) as described in Materials and methods. Nuclei stained with Hoechst, GFP ﬂuorescence of RF177-
infected cells, and merged images (overlay) are also shown. Arrows identify VP22 or GCT-VP22 association with marginalized chromatin.
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Fig. 7. Alignment of the carboxy-termini of three human α-herpesvirus VP22
homologues. The VP22 termini of HSV-1, HSV-2, VZV, and GCT-VP22 (RF177) (lines
1–4) were aligned using a computational algorithm as described in Materials and
methods. The asterisks and the dot mark conserved and similar amino acid identities
between the homologues, respectively. The box marks a six amino acid stretch of
conserved identities comprising the putative human α-herpesvirus VP22 virion
packaging signal (VPS) motif. Line 5 — location of the pat4 nuclear localization signal
motif. Relevant amino acid position numbers are shown on both sides of the sequences.
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antibody used in this study showed little to no reactivity with VP22 in
mock-infected V49 cells (Figs. 6B, panel 6 and C, panel 8). VP22 in
uninfected V49 cells was readily detected with a low dilution of the
VP22 amino-terminal speciﬁc polyclonal antibody RGST49, as
expected (Pomeranz and Blaho, 2000), and localized to nuclei in the
absence of other viral proteins (Fig. 6A, panel 2).
In HSV-1(F)-infected Vero and V49 cells, 22-3 detected nuclear
and, perhaps, microtubule-associated (Kotsakis et al., 2001) VP22 (Fig.
6B, panels 2 and 4). Marginalized chromatin was readily observed as
bright, dense Hoechst staining in the infected cells (Fig. 6B, panels 1
and 3) and a portion of nuclear full-length VP22 associated with it
(compare panel 2 with 1), as expected (Lopez et al., 2008). Based on
our control studies described above, these signals represent full-
length VP22 which was newly synthesized during infection and
indicate that monoclonal antibody 22-3 could speciﬁcally detect VP22
in infected Vero and V49 cells by indirect immunoﬂuorescence. In
control immunoblotting studies, infection of the V49 cells with RF177
did not detectably increase the expression of full-length VP22 (data
not shown). No 22-3 immune reaction or GFP signal was detected in
mock-infected V49 cells (Fig. 6C, panels 8 and 9).
Bright 22-3 antibody staining which directly corresponded to GFP
ﬂuorescence was observed in nuclei as well as in perinuclear regions
of RF177-infected Vero cells (Fig. 6C, compare panel 2 with 3),
consistent with our previous observations in live-infected Vero cells
(Fig. 5). Although both 22-3 staining and GFP ﬂuorescence was
observed in the cytoplasm of RF77-infected V49 cells, these signals
were enhanced in V49 nuclei, compared with the staining patterns
seen in Vero cells (Fig. 6C, compare panels 5 and 6 with 2 and 3). It is
of particular interest and signiﬁcance that a portion of the nuclear
GCT-VP22 signal was associated with regions of marginalized
chromatin (compare panel 6 with 4). VP22 was recently reported to
localize to areas of marginalized chromatin and dispersed nucleoli
(Lopez et al., 2008). Importantly, this represents a novel ﬁnding and
implies that the 15 amino acid portion of VP22 present in GCT-VP22
may play a role in VP22's association with marginalized chromatin.
Taking the results of Figs. 5 and 6 together, it appears that either in
live or ﬁxed cells, the presence of full-length VP22 in the V49 cells
seemed to increase the nuclear detection of GCT-VP22. This enhanced
GCT-VP22 localization in nuclei may suggest a possible interaction
between the full-length VP22 stably expressed in the V49 cells and the
15 carboxy-terminal amino acids of VP22 in GCT-VP22. Thus, VP22
may serve as a binding partner for GCT-VP22. A possible self-
interaction of VP22 has been reported recently based on a yeast
two-hybrid analysis (Lee et al., 2008; Vittone et al., 2005). Our results
may corroborate these ﬁndings and extend them, inasmuch as they
imply that the VP22 multimerization domain, or at least a portion of a
bi-partite domain, might be situated within the carboxy-terminal 15
amino acids of VP22. Since GCT-VP22 contains the pat4 sequence, it is
possible that this motif also plays a role in the targeting of this
chimeric molecule during infection.
Discussion
We previously described the generation of recombinant virus HSV-
1(RF177) (Pomeranz and Blaho, 2000; Yedowitz et al., 2005). In this
study, we characterized the biological behavior of GCT-VP22, a novel
VP22-carboxy-terminal GFP fusion protein which is detected in
RF177-infected cells. Our key ﬁndings may be summarized as follows.
(i) GCT-VP22 is packaged into RF177 virions
In general, it is relatively difﬁcult to detect incoming VP22 (i.e.,
virion derived) by indirect immunoﬂuorescence or immunoblotting
(Fig. 3A) methods (Elliott and O'Hare, 1999; Morrison, Wang, and
Meredith, 1998; Pomeranz and Blaho, 1999; Pomeranz and Blaho,2000). The reason for this is unknown but it may imply that incoming
VP22 is either rapidly degraded or diffused. That GCT-VP22 was
detected at 1 and 3 hpi during RF177 infection was, therefore,
surprising. Since GCT-VP22 is expressed from the strong CMV IE
promoter (Pomeranz and Blaho, 2000), it was synthesized at a high
enough levels that it was incorporated into virions. It is also
conceivable the incoming GCT-VP22 may be more stable than VP22.
(ii) The VP22 portion of GCT-VP22 contains a six amino acid region of
identity which is conserved among the human α-herpesvirus VP22
homologues
The important issue is how GCT-VP22 gets incorporated in virions.
The previous results suggest that the 15 amino acid domain of VP22
present in GCT-VP22 is sufﬁcient to target the chimeric protein into
RF177 virions. Since such a signal might be expected to be conserved
among other herpesvirus VP22 homologues, we performed a
computer analysis (Fig. 7) using the ClustalW alignment algorithm
as described in Materials and methods. While other VP22 homo-
logues, such as that of herpes B virus (Cercopithecine herpesvirus 1;
the α-herpesvirus of macaque monkeys) (Perelygina et al., 2003),
possessed regions of partial identity with GCT-VP22, seven out of
ﬁfteen amino acids, A-R-S-A-S-R (290ARSASR295), were conserved
between the HSV-1, HSV-2, and VZV VP22 homologues (Fig. 7). While
this sequence is contiguous with that of the HSV-1 and HSV-2 pat4
motif, the VZV homologue does not appear to possess pat4 (line 5).
We also performed a similar analysis using the other HSV-1 tegument
proteins VP16, VP13/14, and vhs. We did not detect the ARSASR
sequence and were unable to identify a similarly conserved motif in
each of these proteins. HSV-1 and HSV-2 are more closely related to
each other than both of them are to VZV (Davison, 2002); full-length
VP22 homologues of HSV-1 and HSV-2 share about 69% conserved
identity with each other while the VP22 homologue of VZV shares
about 20% conserved identity with the homologue from HSV-1 (as
determined by the MatrixAlign algorithm of MacVector, data not
shown). Therefore, it was not surprising that the sequence of the VZV
VP22 homologue was aligned by insertion of a gap (Fig. 7, line 3).
Based on our ﬁndings, we propose that the motif, 290ARSASR295, may
represent a humanα-herpesvirus VP22 virion packaging signal (VP22
VPS).
The recent reports that the last 89 amino acids of VP22 (out of 301)
was required for VP22 incorporation into virions (Hafezi et al., 2005;
Murphy et al., 2008; O'Regan et al., 2007) strongly supports the
validity of our hypothesis. Since it is generally assumed that HSV
virions acquire their ﬁnal tegument and envelope in the cytoplasm,
packaging of GCT-VP22 should also occur in the cytoplasm at the trans
Golgi compartment or after interacting with glycoproteins at the Golgi
(Mettenleiter, 2002; Mettenleiter, 2004; Sugimoto et al., 2008;
Vittone et al., 2005). As interactions of VP22 with gD, gE, gI, and gM
have been reported (Chi et al., 2005; Farnsworth, Wisner, and
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VP22 might associate with these as well. Thus, further characteriza-
tions of the behavior of GCT-VP22 in our RF177 system should provide
important new information regarding HSV virion assembly.
Several important questions remain. Assuming the putative VP22
VPS functions as a motif for virion targeting, do other tegument
proteins share this or a similar VPS? Our initial survey of vhs, VP13/14,
and VP16 did not identify clear homologues to the VP22 VPS. Of
course, this does not preclude the possibility that VPS's may be
distinct for each protein. Another important observation was that
Δ212 is also packaged in RF177 virions (Fig. 4) (Pomeranz and Blaho,
2000). Thus, the putative VP22 VPS in GCT-VP22 may function as a
primary packaging signal but at least one other signal likely exists in
Δ212. One interpretation of this is that the VPS in GCT-VP22 is
sufﬁcient but not necessary for packaging. Since our results imply that
VP22 and GCT-VP22 may interact, then the proposed two packaging
signals on full-length VP22 may interact. It may be that the VPS
functions to enhance packaging. Thus, without it, Δ212 is only
packaged at low levels as we observe (Fig. 4, Pomeranz, 2000). Such
a model would also be consistent with the recent studies of Elliott
which conclude that the carboxy-terminal third of VP22 is sufﬁcient
for virion packaging but an additional internal domain likely also plays
a role (Hafezi et al., 2005). Studies currently underway to molecularly
characterize the putative VP22 VPS should critically evaluate these
predictions.
(iii) Full-length VP22 may increase the amount of nuclear GCT-VP22
This conclusion is based in the observation that GCT-VP22
demonstrated somewhat enhanced live nuclear localization following
RF177 infection of VP22-expressing cells. This ﬁnding suggests that
the association with VP22 inside infected cells may inﬂuence the
localization of GCT-VP22. Self-associations of a number of HSV-1
tegument proteins, including VP22, have been described based on
results from two-hybrid analyses (Lee et al., 2008; Vittone et al.,
2005). An earlier biochemical characterization of VP22 by O'Hare's
group indicated that, in solution, VP22 likely dimerizes and is capable
of forming higher order complexes, which may include additional
viral proteins (Mouzakitis et al., 2005). These authors concluded that
carboxy-terminal determinants were required for stabilizing such
assembles. Our results support these studies and extend them. It
appears that the last 15 amino acids of VP22 are capable, in someway,
of associating with full-length VP22. One consequence of this
interaction may be to support nuclear translocation of GCT-VP22 but
not GFP. This raises the intriguing possibility that regulated VP22
nuclear translocation during infection requires either self-association
or complex formationwith other viral proteins. It should be noted that
recent indirect-immune (Yedowitz et al., 2005) and live ﬂuorescence
(Donnelly and Elliott, 2001a; Donnelly and Elliott, 2001b; Hutchinson
et al., 2002; Sugimoto et al., 2008) studies indicate that the kinetics
and environment of VP22's subcellular localizations differ from that of
the other major tegument proteins vhs, VP16, and VP13/14.
Cellular localizations of full-length VP22 appear tightly regulated
since the protein is capable of both cytoplasmic and nuclear
accumulations and it may interact with other proteins or even
transcripts (Aints et al., 2001; Brignati et al., 2003; Elliott, Mouzakitis,
and O'Hare, 1995; Harms et al., 2000; Kotsakis et al., 2001; Martin et
al., 2002; Pomeranz and Blaho, 1999; Sciortino et al., 2002; Vittone et
al., 2005). That GCT-VP22 localizes to the nucleus is consistent with
previous reports that the carboxy-portion of VP22 facilitates the
nuclear association of GFP-VP22 fusion constructs (Brignati et al.,
2003; Elliott and O'Hare, 1997; Fang et al., 1998). Although, GCT-VP22
is small enough to pass freely through the nuclear pore by diffusion
without use of energy, it also contains a putative pat4 (Kotsakis et al.,
2001) nuclear localization signal motif,295RPRR298 (Fig. 1). A recent
study by Zheng et al., implicated a related motif, 130PRPR133, in thenuclear localization of transiently expressed BHV-1 VP22 fused to GFP
(Zheng et al., 2005). Thus, the pat4 motif may play a role in the
localization of GCT-VP22.
Of course, the interplay between different localization signals/
domains of VP22 may only be part of the complex cellular localization
of VP22 and GCT-VP22. Control mechanisms such as phosphorylation
or other modiﬁcation may inﬂuence the localization of VP22 and CGT-
VP22 as well. Phosphorylation or dephosphorylation in the vicinity of
an NLS may play a role in the intracellular distribution of proteins
(reviewed in Jans and Hubner, 1996; Jans, Xiao, and Lam, 2000). VP22
is a virion phosphoprotein (Blaho, Mitchell, and Roizman,1994; Elliott,
O'Reilly, and O'Hare, 1996; Elliott, O'Reilly, and O'Hare, 1999; Gibson
and Roizman, 1974; Pomeranz and Blaho, 1999; Pomeranz and Blaho,
2000) and phosphorylation of VP22 in the incoming virion has been
proposed to be a signal for detegumentation (Morrison, Wang, and
Meredith, 1998). However, VP22 may also remain associated with the
capsid through the disassembly step at the plasma membrane and
might play a role in capsid association with the nuclear pore complex
(Chi et al., 2005; Ojala et al., 2000). While two putative phosphoryla-
tion sites of VP22, serine 292 and serine 294 (Elliott, O'Reilly, and
O'Hare, 1996; Elliott, O'Reilly, and O'Hare, 1999), are contiguous with
the pat4 motif (Fig. 1, line 7), these residues are not phosphorylation
sites on HSV-2 VP22 (Geiss et al., 2004; Geiss et al., 2001). Therefore,
phosphorylation of GCT-VP22 may also occur and this might have an
effect on its nuclear import (Hubner, Xiao, and Jans, 1997). Additional
detailed biochemical analyses are currently underway to address this
issue.
(iv) GCT-VP22 associates with marginalized chromatin
Since we only looked at late times post infection, this effect may
simply be due to nucleopathic viral effect. It has been well described
that an orderedmarginalization of chromatin and dispersal of nucleoli
occurs during wild type HSV-1 infection (Calle et al., 2008; Hampar
and Ellison, 1961; Lopez et al., 2008; Lymberopoulos and Pearson,
2007; Roizman and Knipe, 2001; Roizman, 1974; Simpson-Holley et
al., 2005). Full-length VP22 was shown to associate with dispersed
nucleolin (Lopez et al., 2008). HSV-1 infection reduces the level of
rRNA synthesis and the nucleolus may be gradually pushed to the
nuclear border by the formation of replication compartments (Besse
and Puvion-Dutilleul, 1996). While the nucleolus is the site of
ribosome biogenesis and it has been implicated in controlling
regulatory processes, such as the cell cycle (Mayer and Grummt,
2005; Olson, 2004; Pederson, 1998; Politz et al., 2005), a number of
HSV-1 proteins interact with the nucleolus (Leopardi and Roizman,
1996; Mears, Lam, and Rice, 1995; Morency et al., 2005). VP22, along
with VP13/14 and US11, has been reported to bind RNAs in vitro
(Roller and Roizman, 1990; Sciortino et al., 2002). US11 is another
virion tegument protein which is known to localize to the nucleolus
(MacLean, Rixon, and Marsden, 1987; Roller et al., 1996). These
circumstantial observations imply that VP22 and GCT-VP22 may also
be nucleolar-interacting proteins.
A key question is how VP22 and GCT-VP22 interact with margin-
alized chromatin and, perhaps, nucleoli. GCT-VP22 contains the pat4
nuclear localization sequence motif (Fig. 7) which we have suggested
above plays a role in GCT-VP22's enhanced nuclear accumulation in
the presence of VP22. However, it has been reported that signals like
pat4 overlap, in part, with nucleolar localization signals (Hiscox, 2002;
Rowland and Yoo, 2003). In addition, signals for nucleolar localization
are often linked to nuclear localization signals, forming “extended”
motifs (Yamada et al., 1999). Thus, it is conceivable that the pat4 in
GCT-VP22 is acting to target this GFP fusion protein to marginalized
chromatin (and nucleoli). It remains to be determined whether this
potential association with condensed chromatin is important in the
process by which GCT-VP22 and VP22 become packaged into
infectious virions.
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Cells and virus
African green monkey kidney (Vero) cells were obtained from the
American Type Culture Collection and maintained in Dulbecco's
modiﬁed Eagle's medium (DMEM) supplemented with 5% fetal
bovine serum (5% FBS). V49 are VP22-expressing Vero cells
(Pomeranz and Blaho, 2000) and were maintained in 5% FBS and
containing G418 (1 mg/ml; Gibco-BRL). HSV-1(F) is the wild type
virus strain used in this study. HSV-1(RF177), referred to as RF177,
synthesizes a VP22 truncation protein (Δ212) and expresses GFP
under control of a cytomegalovirus promoter (Pomeranz and Blaho,
2000). The RF177 stocks used in these studies were generated using
Vero cells and are, therefore, virion-negative for full-length VP22.
Virus stocks were prepared and titered as described previously
(Pomeranz and Blaho, 2000).
Synchronized infections
Synchronized infections are deﬁned as uniform staining in all cells
in a microscopic ﬁled at a given time post infection, as determined by
indirect immunoﬂuorescencewith antibodies speciﬁc for unique HSV-
1 polypeptides (Pomeranz and Blaho, 1999). Vero or V49 cells were
incubated on ice at 4 °C for at least 15 min prior to the addition of
virus. The cells were then inoculated with virus (MOI of 15) at 4 °C.
After allowing the virus to adsorb for 1 h, the cells were rinsed once
with 4 °C phosphate-buffered saline (PBS) and warm (37 °C) DMEM
supplementedwith 5% newborn calf serum (5% NBCS) was added, and
the cells were incubated at 37 °C for 18 h.
Infected whole cell extracts
Approximately 2×106 infected cells were harvested directly into
the medium by gentle scraping, brieﬂy pelleted by low speed
centrifugation, and washed once in 140 mM NaCl, 3 mM KCl, 10 mM
Na2HPO4, 1.5 mM KH2PO4, pH 7.5 (PBS). Whole cell extracts were
prepared by adding PBS containing 1% deoxycholate and 1% NP40 and
the following protease inhibitors; 10 mM L-1-chlor-3-(4-tosylamido)-
7-amino-2-heptanon-hydrochloride (TLCK), 10 mM L-1-chlor-3 (4-
tosylamido)-4-phenyl-2-butanone (TPCK), and 100 mM phenyl-
methylsulfonyl ﬂuoride (PMSF), followed by sonication using a
Bronson soniﬁer. Protein concentrations of infected cell extracts
were determined using amodiﬁed Bradford assay (Bio-Rad) according
to the manufacturer's speciﬁcations.
Virion preparations
Preparations of puriﬁed virionswere performed exactly as described
previously (Pomeranz and Blaho, 1999). Approximately 2×108 infected
Vero cells (MOI=5) were harvested directly in medium by gentle
scraping at 24 hpi and pelleted by low speed centrifugation. Cells were
swollen on ice prior to lysis using a Dounce homogenizer. Intracellular
virions were puriﬁed from dextran T10 (Pharmacia) gradients and
isolated virions were concentrated by high speed ultracentrifugation
(180,000 ×g). This procedure yielded approximately 106 PFU per ml of
virion stock per ml. Virion preparations were tested for the absence of
contaminating protein by immunoblotting for tubulin; no anti-tubulin
immune reactivity was detected in any virion preparation.
Denaturing gel electrophoresis and immunoblotting
Equal amounts (50 μg) of infected cell protein were separated in
15% SDS-polyacrylamide gels cross-linked with N, N′-diallyltartardia-
mide (DATD), electrically transferred to nitrocellulose, and probed
with relevant primary antibodies. Horseradish peroxidase-conjugatedanti-rabbit or anti-mouse IgG (Amersham) secondary antibodies were
diluted 1:1000 in PBS and incubatedwith the blots for 1 h. Speciﬁc viral
bands were detected following development with enhanced chemilu-
minescence reagents (Amersham) or Lumi-light western blotting
substrate (Roche Diagnostics). Alkaline phosphatase-conjugated goat
anti-rabbit and anti-mouse IgG secondary antibodies (Southern
Biotech) were used at 1:1000 in PBS containing 5% milk. Prestained
molecular weight markers (Gibco-BRL) were included in all gels.
Immunological reagents
RGST49 is a rabbit polyclonal antibody speciﬁc for the amino-
terminal portion of the VP22 protein (Blaho, Mitchell, and Roizman,
1994; Pomeranz and Blaho, 1999) and was used at dilutions of 1:750
for immunoﬂuorescence and 1:1000 for immunoblotting. Puriﬁed
hybridoma 22-3 monoclonal antibody speciﬁc for the VP22 carboxy-
terminus (Geiss et al., 2001) was used at dilutions of 1:1000 for
immunoblotting and 1:100 for immunoﬂuorescence. Polyclonal anti-
GFP antibody (Clontech) was used at 1:4000 andmonoclonal anti-GFP
antibody (JL-8; BD Biosciences) was used at 1:1000 for immunoblot-
ting. Monoclonal anti-ICP4 antibody H1114 (Goodwin) was used at
1:1000. Anti-nucleolin monoclonal antibody (C23; Santa Cruz
Biotechnology) was used at 1:50 for indirect immunoﬂuorescence;
for this procedure, cells were blocked in 1.5% normalmouse IgG (Santa
Cruz Biotechnology). Alexa568-conjugated anti-rabbit IgG and anti-
mouse IgG (Molecular Probes) and ﬂuorescein isothiocyanate-
conjugated IgG (Sigma) were used at dilutions of 1:750 in 1% BSA
for immunoﬂuorescence.
Indirect immunoﬂuorescence and live cell microscopy
Cells were prepared for indirect immunoﬂuorescence by washing
twice in PBS prior to ﬁxation in 2.5% methanol-free formaldehyde
(Polysciences, Inc.) for 20 min at room temperature. Next, the cells
were washed twice again with PBS, permeabilized with 100% acetone
at−20 °C for 4 min, rinsed twice again in PBS, and then blocked for at
least 8.5 h at 4 °C in 1% BSA containing 10 μg of pooled human Ig
(mainly IgG) (Sigma) per ml. As noted above, with anti-nucleolin
antibody, cells were incubated for 20 min in 1.5% mouse pre-immune
serum. The cells were then rinsed twice in PBS and each primary
antibody was added for 1 h. After extensive rinsing with PBS, the
appropriate secondary antibody was added and incubated for an
additional 1 h. Finally, the cells were preserved in ProLong Antifade
reagent (Molecular Probes). Hoechst 33258DNAdye (Sigma)was used
for staining nuclei at a ﬁnal concentration of 0.05 μg/ml. Cells were
visualized with the appropriate ﬁlter on an Olympus IX70/IX-FLA
inverted microscope with an attached Sony DKC-5000 digital camera
linked to a PowerMac G3 and processed through Adobe Photoshop.
Sequence analysis and computer imaging
Amino acid alignments of VP22 homologues were performed by
the ClustalW alignment algorithm using the MacVector sequence
analysis application. A ﬁle containing the last 15 amino acids of VP22
was compared to all proteins in the SwissProt database. The following
are relevant genome accession numbers: HSV-1, AAT11799; HSV-2,
NP_044519; Varicellovirus (VZV), P09272. Immunoblots were digi-
tized at 600 to 2400 dots per inch using an AGFA Arcus II scanner
linked to a Macintosh G3 PowerPC workstation. Raw digital images,
saved as tagged image ﬁles (TIF) using Adobe Photoshop were
organized into ﬁgures using Adobe Illustrator.
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